Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials

New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review

“…In a new meta-regression analysis in T2D patients (60,079 patients, 30,693 with GLP-1 RAs) reductions of HbA1C were associated with the reduction of three-point MACE-cardiovascular death, myocardial infarction, or stroke [174]. A three-point MACE (Log RR −0.290, p = 0.012) was observed, with an estimated RR reduction of 25% for each 1% absolute reduction in HbA1C levels [175]. Body weight loss was associated with the reduction of a three-point MACE (Log RR −0.068], p = 0.047), with an estimated RR reduction of 7% for each 1 kg reduction in body weight, while reductions of SBP and LDL-C were not associated with the reduction of three-point MACE [175].…”

“…Body weight loss was associated with the reduction of a three-point MACE (Log RR −0.068], p = 0.047), with an estimated RR reduction of 7% for each 1 kg reduction in body weight, while reductions of SBP and LDL-C were not associated with the reduction of three-point MACE [175]. Thus, early treatment with GLP-1 RA may either mitigate or delay the risk of future HF in patients with T2D [175].…”

How to assess kidney outcomes in obese people with substantial weight loss: the case of GLP1- and dual-receptor agonists

“…A recent systematic review and meta-analysis by Sattar and colleagues assessed published, randomized, placebo-controlled trials testing either injectable or oral GLP1-RAs in patients with type 2 diabetes [ 11 ]. In those studies, weight loss was modest in the order of 1 to 4 kg vs. placebo [ 12 ]. Six of the eight trials that reported cardiovascular outcomes also reported kidney events.…”